Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Pioglitazone vs combination for NAFLD in diabetic patients
IRCT20230903059343N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin and pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Arak University of Medical Sciences. Started Oct 2023; status: completed.
02
Drugs
empagliflozinpioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20230903059343N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230903059343N1.